Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Abeona Therapeutics Stock Dropped 12% Today

By Brian Orelli, PhD - May 18, 2018 at 5:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A clinical trial update for AB-102 didn't go far enough.

What happened

Shares of gene therapy expert Abeona Therapeutics (ABEO 8.58%) closed down 12% on Friday after the company reported updated data from a phase 1/2 trial testing ABO-102, a treatment for a rare genetic disease called Sanfilippo syndrome type A, at the 21st annual meeting of the American Society for Gene and Cell Therapy.

So what

With shares having more than tripled over the past year, it may be more what Abeona didn't say in its update than what it did say that caused the stock to slip today.

But first let's start with the data it did present, which seemed promising enough. Abeona has been following some of the patients for 18 months and the treatment doesn't seem to have waned much -- as measured by biomarkers -- past the initial decline seen around 180 days. In the later cohorts of patients that were treated with higher doses of ABO-102, the 180-day data look better, although those patients haven't been followed as long, so we don't have data out to 18 months.

Doctor listens to boy's heart with a stethoscope

Image source: Getty Images.

Investors likely hit the sell button today because of a lack of any data beyond biomarkers and some data on liver size, which was also trending in the right direction. While biomarkers and liver size are likely to be a good indicator that the drug is working, patients' function, measured though neurocognitive scores, is ultimately what doctors and the parents of the kids who have Sanfilippo syndrome really care about.

Now what

Investors will just have to wait until the next update to (hopefully) get more information on the neurocognitive scores of the patients. Presumably investors will also get an update shortly about the plan for the next clinical trial for ABO-102, which should be designed to get the treatment approved.

In the meantime, Abeona has other programs. EB-101, a gene-corrected skin graft cell therapy for patients with recessive dystrophic epidermolysis bullosa, is ready to enter phase 3 development later this year. AB-101, a gene therapy that treats another type of Sanfilippo syndrome, produced positive, albeit early, data in February.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abeona Therapeutics Inc. Stock Quote
Abeona Therapeutics Inc.
$0.20 (8.58%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.